Streck Enters into Distribution Agreement with HiSS Diagnostics
By LabMedica International staff writers Posted on 09 Feb 2017 |
Streck, Inc., which develops and manufactures products for clinical and research laboratories, has entered into a distribution agreement for its molecular and cell stabilization products with HiSS Diagnostics GmbH, a distributor of medical laboratory products.
Streck offers automated erythrocyte sedimentation rate instruments, kits and reagents, and blood collection tubes for sample collection, stabilization and transportation. Its product portfolio also includes flow cytometry, body fluids and urinalysis instruments, as well as molecular diagnostic instruments and consumables.
Streck’s cell stabilization products include Cell-Free DNA Urine Preserve, a formaldehyde-free liquid reagent that stabilizes cell-free DNA (cfDNA) in urine; Cell-Free DNA BCT CE, a direct-draw blood collection tube which stabilizes nucleated blood cells and prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery and diagnostic assay development; and Cell-Free RNA BCT CE, a blood collection tube with a patented preservative which stabilizes circulating RNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage. The company’s molecular product line includes Streck Antibiotic Resistance Monitoring & Detection (ARM-D) kits, PhilisaFAST DNA Polymerase and Streck’s Real-Time PCR System, the Zulu RT.
HiSS Diagnostics sells products for medical microbiology, immunology and quality assurance in the medical laboratory. Its product offerings also include a full range of antibodies for flow cytometry and hematology, research and diagnostics products for next-generation sequencing, microarrays and qPCR in oncology and hematology and other applications, isolation and sequencing of cell-free DNA in liquid biopsy.
“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, HiSS will be able to provide excellent local support to our German customers.”
Streck offers automated erythrocyte sedimentation rate instruments, kits and reagents, and blood collection tubes for sample collection, stabilization and transportation. Its product portfolio also includes flow cytometry, body fluids and urinalysis instruments, as well as molecular diagnostic instruments and consumables.
Streck’s cell stabilization products include Cell-Free DNA Urine Preserve, a formaldehyde-free liquid reagent that stabilizes cell-free DNA (cfDNA) in urine; Cell-Free DNA BCT CE, a direct-draw blood collection tube which stabilizes nucleated blood cells and prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery and diagnostic assay development; and Cell-Free RNA BCT CE, a blood collection tube with a patented preservative which stabilizes circulating RNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage. The company’s molecular product line includes Streck Antibiotic Resistance Monitoring & Detection (ARM-D) kits, PhilisaFAST DNA Polymerase and Streck’s Real-Time PCR System, the Zulu RT.
HiSS Diagnostics sells products for medical microbiology, immunology and quality assurance in the medical laboratory. Its product offerings also include a full range of antibodies for flow cytometry and hematology, research and diagnostics products for next-generation sequencing, microarrays and qPCR in oncology and hematology and other applications, isolation and sequencing of cell-free DNA in liquid biopsy.
“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, HiSS will be able to provide excellent local support to our German customers.”
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus